Ipsen announced on Friday that the pivotal Phase II FALKON trial for its experimental drug, fidrisertib, targeting fibrodysplasia ossificans progressiva (FOP), did not meet its primary endpoint, leading to the termination of the study.

The drug was intended to reduce the volume of abnormal new bone formation (heterotopic ossification or HO) in adults and children with FOP compared to placebo, according to the company statement.

However, Ipsen stated that fidrisertib was generally well tolerated, with no safety concerns identified during the trial.

(Written by Coralie Lamarque; edited by Augustin Turpin)